315 related articles for article (PubMed ID: 16937039)
1. Molecular mechanisms of cholestasis.
Zollner G; Trauner M
Wien Med Wochenschr; 2006 Jul; 156(13-14):380-5. PubMed ID: 16937039
[TBL] [Abstract][Full Text] [Related]
2. Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis.
Trauner M; Wagner M; Fickert P; Zollner G
J Clin Gastroenterol; 2005 Apr; 39(4 Suppl 2):S111-24. PubMed ID: 15758646
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis.
Wagner M; Trauner M
Ann Hepatol; 2005; 4(2):77-99. PubMed ID: 16010241
[TBL] [Abstract][Full Text] [Related]
4. Genetic cholestasis, causes and consequences for hepatobiliary transport.
Jansen PL; Sturm E
Liver Int; 2003 Oct; 23(5):315-22. PubMed ID: 14708891
[TBL] [Abstract][Full Text] [Related]
5. Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis.
Meng Q; Chen XL; Wang CY; Liu Q; Sun HJ; Sun PY; Huo XK; Liu ZH; Yao JH; Liu KX
Toxicol Appl Pharmacol; 2015 Mar; 283(3):178-86. PubMed ID: 25655198
[TBL] [Abstract][Full Text] [Related]
6. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations.
Zollner G; Marschall HU; Wagner M; Trauner M
Mol Pharm; 2006; 3(3):231-51. PubMed ID: 16749856
[TBL] [Abstract][Full Text] [Related]
7. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.
Wagner M; Halilbasic E; Marschall HU; Zollner G; Fickert P; Langner C; Zatloukal K; Denk H; Trauner M
Hepatology; 2005 Aug; 42(2):420-30. PubMed ID: 15986414
[TBL] [Abstract][Full Text] [Related]
8. [New molecular aspects of cholestatic liver diseases].
Trauner M; Fickert P; Stauber RE
Z Gastroenterol; 1999 Jul; 37(7):639-47. PubMed ID: 10458013
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of hepatocellular transporters.
Pauli-Magnus C; Meier PJ
Pharmacogenetics; 2003 Apr; 13(4):189-98. PubMed ID: 12668915
[TBL] [Abstract][Full Text] [Related]
10. New molecular insights into the mechanisms of cholestasis.
Wagner M; Zollner G; Trauner M
J Hepatol; 2009 Sep; 51(3):565-80. PubMed ID: 19595470
[TBL] [Abstract][Full Text] [Related]
11. Bile salt excretory pump: biology and pathobiology.
Suchy FJ; Ananthanarayanan M
J Pediatr Gastroenterol Nutr; 2006 Jul; 43 Suppl 1():S10-6. PubMed ID: 16819395
[TBL] [Abstract][Full Text] [Related]
12. Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism.
Crosignani A; Podda M; Bertolini E; Battezzati PM; Zuin M; Setchell KD
Hepatology; 1991 Jun; 13(6):1076-83. PubMed ID: 2050325
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of heme oxygenase induction in ethinylestradiol-induced cholestasis.
Muchova L; Vanova K; Suk J; Micuda S; Dolezelova E; Fuksa L; Cerny D; Farghali H; Zelenkova M; Lenicek M; Wong RJ; Vreman HJ; Vitek L
J Cell Mol Med; 2015 May; 19(5):924-33. PubMed ID: 25683492
[TBL] [Abstract][Full Text] [Related]
14. Pharmacotherapy of cholestatic liver diseases.
Paumgartner G
J Dig Dis; 2010 Jun; 11(3):119-25. PubMed ID: 20579215
[TBL] [Abstract][Full Text] [Related]
15. Excessive bilirubin elevation in a patient with hereditary spherocytosis and intrahepatic cholestasis.
Wree A; Canbay A; Müller-Beissenhirtz H; Dechêne A; Gerken G; Dührsen U; Lammert F; Nückel H
Z Gastroenterol; 2011 Aug; 49(8):977-80. PubMed ID: 21811948
[TBL] [Abstract][Full Text] [Related]
16. Medical treatment of cholestatic liver diseases: From pathobiology to pharmacological targets.
Paumgartner G
World J Gastroenterol; 2006 Jul; 12(28):4445-51. PubMed ID: 16874853
[TBL] [Abstract][Full Text] [Related]
17. Geniposide attenuates ANIT-induced cholestasis through regulation of transporters and enzymes involved in bile acids homeostasis in rats.
Wang L; Wu G; Wu F; Jiang N; Lin Y
J Ethnopharmacol; 2017 Jan; 196():178-185. PubMed ID: 27988401
[TBL] [Abstract][Full Text] [Related]
18. [Molecular mechanisms of bile formation and cholestatic diseases].
Poupon R
Bull Acad Natl Med; 2003; 187(7):1261-74; discussion 1274-6. PubMed ID: 15146603
[TBL] [Abstract][Full Text] [Related]
19. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases.
Zollner G; Fickert P; Zenz R; Fuchsbichler A; Stumptner C; Kenner L; Ferenci P; Stauber RE; Krejs GJ; Denk H; Zatloukal K; Trauner M
Hepatology; 2001 Mar; 33(3):633-46. PubMed ID: 11230744
[TBL] [Abstract][Full Text] [Related]
20. Genetics of familial intrahepatic cholestasis syndromes.
van Mil SW; Houwen RH; Klomp LW
J Med Genet; 2005 Jun; 42(6):449-63. PubMed ID: 15937079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
